Principal Investigator

Franziska Michor, Ph.D.

Franziska Michor outside the Center for Life Sciences

The Michor lab is interested in cancer evolution through the use of integrative data science, experimental, clinical, and population science approaches. We develop methodology to develop, analyze, and integrate diverse data types and design predictive algorithms using approaches from applied mathematics, statistics, bioinformatics, and machine learning.


Image of Franziska  Michor, Ph.D.

Franziska Michor, Ph.D.

  • Professor of Stem Cell and Regenerative Biology
  • Professor of Computational Biology
    Department of Data Sciences, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard T.H. Chan School of Public Health
  • Director
    Dana-Farber Cancer Institute Physical Sciences-Oncology Center and the Center for Cancer Evolution


Franziska Michor is a Professor of Computational Biology in the Department of Data Sciences at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and a Professor of Stem Cell and Regenerative Biology in HSCRB.

Michor completed her undergraduate training in mathematics and molecular biology from the University of Vienna, Austria, and her Ph.D. from the Department of Organismic and Evolutionary Biology at Harvard University. After being awarded a fellowship from the Harvard Society of Fellows, she accepted a faculty position in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. In 2010 she moved back to Boston and has since been directing the Dana-Farber Cancer Institute Physical Sciences-Oncology Center and the Center for Cancer Evolution.

Michor is the recipient of the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, the Alice Hamilton Award, the Vilcek Prize for Creative Promise in Biomedical Science, the 36th Annual AACR Award for Outstanding Achievement in Cancer Research, and others. Dr. Michor’s laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.

Search Menu